Oncology Archives - Page 2 of 6 - Corcept Therapeutics

Phase 3 Results of Relacorilant + Nab-Paclitaxel v Nab-Paclitaxel In Platinum-Resistant Ovarian Cancer (ROSELLA): Secondary Endpoints

June 19, 2025

Lorusso et al. • 2025 • ESMO Gyn

ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer

June 2, 2025

A. Olawaiye et al. • 2025 •

Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer

March 18, 2024

Colombo et al. • 2024 • SGO 2024 Congress

ROSELLA (GOG-3073, ENGOT-OV72/MITO): A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Platinum-Resistant Ovarian Cancer

November 6, 2023

Lorusso et al. • 2023 • IGCS 2023 Congress

ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer

October 2, 2023

Lorusso et al. • 2023 • ESGO 2023 Congress

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

June 27, 2023

Colombo et al. • 2023 • Journal of Clinical Oncology

The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol

June 6, 2023

Greenstein & Hunt • 2023 • International Immunopharmacology

Selective Glucocorticoid Receptor Modulation Reveals a New Role for CLEC10A in Patients With Solid Tumors

April 17, 2023

Mann et al. • 2023 • AACR 2023

Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators

March 28, 2023

Mallick et al • 2023 • Transl Res.

ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer

March 26, 2023

Alexander Olawaiye et al. • 2023 • SGO Annual Meeting 2023